WO2003057874A1 - Disease markers for renal diseaes and utilization thereof - Google Patents

Disease markers for renal diseaes and utilization thereof Download PDF

Info

Publication number
WO2003057874A1
WO2003057874A1 PCT/JP2002/013777 JP0213777W WO03057874A1 WO 2003057874 A1 WO2003057874 A1 WO 2003057874A1 JP 0213777 W JP0213777 W JP 0213777W WO 03057874 A1 WO03057874 A1 WO 03057874A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
renal
glomerular fibrosis
polynucleotides
disease markers
Prior art date
Application number
PCT/JP2002/013777
Other languages
French (fr)
Inventor
Eiji Sugaru
Junji Ichihara
Mutsuo Taiji
Original Assignee
Sumitomo Pharmaceuticals Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001-401076 priority Critical
Priority to JP2001401076 priority
Application filed by Sumitomo Pharmaceuticals Company, Limited filed Critical Sumitomo Pharmaceuticals Company, Limited
Publication of WO2003057874A1 publication Critical patent/WO2003057874A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/01Hexosyltransferases (2.4.1)
    • C12Y204/0108Ceramide glucosyltransferase (2.4.1.80)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Abstract

Disease markers reflecting renal diseases accompanied by glomerular fibrosis; a method of detecting a renal disease accompanied by glomerular fibrosis using such a disease marker; and a method of screening a drug useful in ameliorating these disease. Namely, polynucleotides having at least 15 consecutive bases in the base sequence of ceramide glucosyltransferase (CGT) gene and/or polynucleotides complementary to these polynucleotides, etc. are used as disease markers for renal diseases accompanied by glomerular fibrosis. A drug for ameliorating renal diseases accompanied by glomerular fibrosis can be screened by bringing a test substance into contact with cells expressing the CGT gene and then examining the occurrence, increase or regulation of the expression of the CGT gene.
PCT/JP2002/013777 2001-12-28 2002-12-27 Disease markers for renal diseaes and utilization thereof WO2003057874A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2001-401076 2001-12-28
JP2001401076 2001-12-28

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002367266A AU2002367266A1 (en) 2001-12-28 2002-12-27 Disease markers for renal diseaes and utilization thereof
JP2003558172A JPWO2003057874A1 (en) 2001-12-28 2002-12-27 Disease markers and the use of renal disease

Publications (1)

Publication Number Publication Date
WO2003057874A1 true WO2003057874A1 (en) 2003-07-17

Family

ID=19189720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/013777 WO2003057874A1 (en) 2001-12-28 2002-12-27 Disease markers for renal diseaes and utilization thereof

Country Status (3)

Country Link
JP (1) JPWO2003057874A1 (en)
AU (1) AU2002367266A1 (en)
WO (1) WO2003057874A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028241A1 (en) * 2004-09-08 2006-03-16 Takeda Pharmaceutical Company Limited Preventive/therapeutic drug for arteriosclerosis
JP2008519840A (en) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイションGenzyme Corporation A method of treatment diabetes
WO2010014554A1 (en) * 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
JP2012504608A (en) * 2008-10-03 2012-02-23 ジェンザイム コーポレーション 2-acylamino-propanol - type glucosylceramide synthase inhibitor
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8716327B2 (en) 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease
US8912177B2 (en) 2007-10-05 2014-12-16 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
WO2017170610A1 (en) * 2016-03-29 2017-10-05 株式会社国際電気通信基礎技術研究所 Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure
US10227323B2 (en) 2014-09-19 2019-03-12 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748868A2 (en) * 1995-06-15 1996-12-18 THE INSTITUTE OF PHYSICAL & CHEMICAL RESEARCH Ceramide glucosyltransferase
US6277574B1 (en) * 1999-04-09 2001-08-21 Incyte Genomics, Inc. Genes associated with diseases of the kidney
US6333408B1 (en) * 1999-03-08 2001-12-25 Kureha Chemical Industry Co., Ltd. Oligonucleotides inhibitors of PAI-1 MRNA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0748868A2 (en) * 1995-06-15 1996-12-18 THE INSTITUTE OF PHYSICAL & CHEMICAL RESEARCH Ceramide glucosyltransferase
US6333408B1 (en) * 1999-03-08 2001-12-25 Kureha Chemical Industry Co., Ltd. Oligonucleotides inhibitors of PAI-1 MRNA
US6277574B1 (en) * 1999-04-09 2001-08-21 Incyte Genomics, Inc. Genes associated with diseases of the kidney

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KODAMA S. ET AL.: "Glycosyl ceramide synthesis in the developing spinal cord and kidney of the twitcher mouse an enzymatically authentic model of human krabbe disease", J. NEUROCHEM., vol. 39, no. 5, 1982, pages 1314 - 1381, XP002965255 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028241A1 (en) * 2004-09-08 2006-03-16 Takeda Pharmaceutical Company Limited Preventive/therapeutic drug for arteriosclerosis
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
US9532976B2 (en) 2004-11-10 2017-01-03 Genzyme Corporation Method of lowering blood glucose
JP2008519840A (en) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイションGenzyme Corporation A method of treatment diabetes
US8716327B2 (en) 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease
US9556155B2 (en) 2006-05-09 2017-01-31 Genzyme Corporation Methods of treating fatty liver disease
US9745294B2 (en) 2007-05-31 2017-08-29 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8940776B2 (en) 2007-05-31 2015-01-27 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8912177B2 (en) 2007-10-05 2014-12-16 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US10220039B2 (en) 2007-10-05 2019-03-05 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
JP2011529500A (en) * 2008-07-28 2011-12-08 ジェンザイム コーポレーション Glucosylceramide synthase inhibitors for the treatment of collapsing glomerulopathy and other glomerular diseases
US8729075B2 (en) 2008-07-28 2014-05-20 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
JP2015131839A (en) * 2008-07-28 2015-07-23 ジェンザイム コーポレーション Glucosylceramide synthase inhibition for treatment of collapsing glomerulopathy and other glomerular disease
WO2010014554A1 (en) * 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US9481671B2 (en) 2008-07-28 2016-11-01 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
JP2012504608A (en) * 2008-10-03 2012-02-23 ジェンザイム コーポレーション 2-acylamino-propanol - type glucosylceramide synthase inhibitor
US9744153B2 (en) 2008-10-03 2017-08-29 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US9272996B2 (en) 2008-10-03 2016-03-01 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US10227323B2 (en) 2014-09-19 2019-03-12 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
JPWO2017170610A1 (en) * 2016-03-29 2018-09-27 株式会社国際電気通信基礎技術研究所 Reduced renal function, at least prevent one disease, or screening method of the candidate substances of the active ingredient for the treatment selected from the group consisting of chronic renal disease and renal failure
WO2017170610A1 (en) * 2016-03-29 2017-10-05 株式会社国際電気通信基礎技術研究所 Screening method for candidate substances for active component to prevent or treat at least one disease selected from the group consisting of renal hypofunction, chronic kidney disease and kidney failure

Also Published As

Publication number Publication date
AU2002367266A1 (en) 2003-07-24
JPWO2003057874A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
AU2001275039A1 (en) Improved nucleic acid modifying enzymes
AU8865998A (en) Improved multiparticulate tablet with quick disintegration
SV2004001904A (en) frits based niobium suboxide
AU8574501A (en) Thiophene derivatives active as kinase inhibitors, process for their preparationand pharmaceutical compositions comprising them
BRPI0707043A2 (en) matrix tablets, matrix tablets to the oxycodone base, tablets, matrix tablets of the manufacturing process and use
CZ296328B6 (en) 17alpha-fluoroalkyl steroids, pharmaceutical compositions in which the steroids are comprised and their use
AU2002365421A1 (en) Methods and compositions for detecting the activation state of the multiple proteins in single cells
HK1050369A1 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof.
EP1254703A3 (en) Matrix storage and dispensing system
WO2003043572A3 (en) Methods and compositions related to irm compounds and toll-like receptor pathways
WO2002012447A3 (en) Isolation and use of solid tumor stem cells
AU2002309803A1 (en) Breath test for assessing diseases, particularly asthma
AU2001234593A1 (en) Compositions and methods for performing biological reactions
JPH01215289A (en) Production of normal human serum albumin a through gene recombination
AU2002338242A1 (en) Memory cell arrays and method for the production thereof
MX9605450A (en) Treatment for atherosclerosis and other cardiovascular and inflammatory diseases.
EP1613741A4 (en) Perivascular mesenchymal precursor cells
WO2004073741A8 (en) Remedy for spinal injury containing interleukin-6 antagonist
AU2002346656A1 (en) Methods for the cost-effective saccharification of lignocellulosic biomass
ZA200300196B (en) Substituted sulfonyl aminomethyl benzoic acid (derivatives) and method for the production thereof.
WO2004047794A3 (en) An allergen dosage form
HK1044963A1 (en) Process for the biological production of 1,3-propanediol
ZA200109859B (en) 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations.
EP1471970A4 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
WO2001079461A3 (en) Polypeptides having haloperoxidase activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003558172

Country of ref document: JP

122 Ep: pct application non-entry in european phase